Stockscreener 앱 받기
5.54
7.05%
-0.42
시간 외 거래:
5.54
전일 마감가:
$5.96
열려 있는:
$5.7
하루 거래량:
3.43M
Relative Volume:
2.64
시가총액:
$479.62M
수익:
-
순이익/손실:
$-168.09M
주가수익비율:
-2.553
EPS:
-2.17
순현금흐름:
$-138.01M
1주 성능:
-7.97%
1개월 성능:
-4.65%
6개월 성능:
-35.95%
1년 성능:
-71.03%
1일 변동 폭
$5.47
$5.86
1주일 범위
$5.47
$6.4899
52주 변동 폭
$5.41
$21.57
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
KURA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
5.54 | 522.05M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura Oncology price target lowered to $27 from $29 at BofA - TipRanks
Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Is Kura Oncology Inc. stock entering bullish territoryDividend Strategy Summary With 10-Year Outlook - Newser
What makes Kura Oncology Inc. stock price move sharplyFree Daily Chart Pattern Stock Forecast - Newser
How hedge fund analytics apply to Kura Oncology Inc. stockROI Focused Setup Screener With Exit Markers - Newser
Order flow analysis tools used on Kura Oncology Inc.Equity Performance Forecast Based on AI Models - Newser
Chart based analysis of Kura Oncology Inc. trendsFree Short Term Buy Zone Stock Alerts - Newser
Candlestick Reversal Detected on Kura Oncology Inc.’s ChartStrong Buy With Technical Confidence Supported - beatles.ru
How to escape a deep drawdown in Kura Oncology Inc.Market Downturn Defense Strategy Analysis - Newser
Kura Oncology shares fall 5.12% intraday despite FDA Priority Review of ziftomenib NDA. - AInvest
Kura Oncology’s Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating - TipRanks
Earnings call transcript: Kura Oncology Q2 2025 shows revenue miss, EPS below forecast - Investing.com
Kura Oncology Inc (KURA) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses By GuruFocus - Investing.com Canada
Kura Oncology Inc (KURA) Q2 2025 Earnings Call Highlights: Strat - GuruFocus
Kura Oncology Advances Cancer Drug Pipeline with FDA Review - TipRanks
Published on: 2025-08-07 23:14:29 - Newser
Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
Kura Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kura Oncology: Q2 Earnings Snapshot - San Antonio Express-News
Kura Oncology Inc earnings missed by $0.34, revenue fell short of estimates - Investing.com South Africa
Kura Oncology Reports Second Quarter 2025 Financial Results - Yahoo Finance
Dimensional US Core Equity 2 ETF (DFAC) Implied Analyst Target Price: $41.37, With 12.92% Upside Expected. - AInvest
Kura Oncology Grants Inducement Stock Options to New Employees Under Nasdaq Listing Rule - AInvest
Kura Oncology KURA Q2 2025 Earnings Preview Upside Potential on Robust Revenue Forecast - AInvest
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology grants stock options to new employees under inducement plan. - AInvest
Cancer Drug Developer Kura Oncology Makes Major Hiring Push: 35 New Scientists Join Precision Medicine Team - Stock Titan
How strong is Kura Oncology Inc. company’s balance sheetUnlock powerful investment tools for free - Jammu Links News
What are the technical indicators suggesting about Kura Oncology Inc.Unlock powerful trading signals and alerts - Jammu Links News
What markets is Kura Oncology Inc. expanding into Is GURE stock a good long term investment optionTremendous gains - Jammu Links News
What institutional investors are buying Kura Oncology Inc. stockTake advantage of unprecedented market momentum - Jammu Links News
What drives Kura Oncology Inc. stock priceUnmatched profit potential - Jammu Links News
What are analysts’ price targets for Kura Oncology Inc. in the next 12 monthsDiscover stocks with explosive upside potential - Jammu Links News
Why is Kura Oncology Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - Jammu Links News
Using flow based indicators on Kura Oncology Inc.Asset Allocation Summary With Future Outlook - Newser
What are the latest earnings results for Kura Oncology Inc.Fast-track wealth growth - Jammu Links News
Kura Oncology targets 2028 MRD-negative CR results for frontline AML trials - MSN
Is Kura Oncology Inc. the Top Chart Pick This WeekOptimized Return Investment Picks - beatles.ru
Why Kura Oncology Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - beatles.ru
How does Kura Oncology Inc. generate profit in a changing economyEntry Signal Report For Beginners - jammulinksnews.com
Kura Oncology Sets Q2 Earnings Date: Cancer Drug Pipeline Update Coming August 7 - Stock Titan
Kura Oncology to Report Second Quarter 2025 Financial Results - The Manila Times
Investor Network: Kura Oncology, Inc. to Host Earnings Call - ACCESS Newswire
Kura Oncology Inc. Recovery Potential Based on Technical ToolsWeekly Return Pick Forecast Reports Show Trend - metal.it
How to use a screener to detect Kura Oncology Inc. breakoutsSwing Trade Signal and Price Prediction - Newser
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):